Skip to main content
Top

23-03-2017 | Diagnosis | Case report | Article

Type III Hypersensitivity Reaction to Subcutaneous Insulin Preparations in a Type 1 Diabetic

Journal: Journal of General Internal Medicine

Authors: Benjamin R. Murray, MPH, Jolene R. Jewell, MD, Kyle J. Jackson, DO, Olabunmi Agboola, MD, Brianna R. Alexander, PharmD, BCPS, Poonam Sharma, MD

Publisher: Springer US

Abstract

Management of type 1 diabetes in patients who have insulin hypersensitivity is a clinical challenge and places patients at risk for recurrent diabetic ketoacidosis (DKA). Hypersensitivity reactions can be due to the patient’s response to the insulin molecule itself or one of the injection’s non-insulin components. It is therefore crucial for clinicians to quickly recognize the type of hypersensitivity reaction that is occurring and identify potentially immunogenic additives for the purpose of directing therapy as various insulin preparations have differing ingredients. We present the case of a 23-year-old diabetic female with common variable immunodeficiency (CVID) and autoimmune enteropathy who developed a type III hypersensitivity reaction to multiple formulations of subcutaneous insulin after years of use and the challenges of devising a long-term management strategy.
Literature
1.
Darmon P, Castera V, Koeppel MC, Petitjean C, Dutour A. Type III allergy to insulin detemir. Diabetes Care. 2005;28(12):2980.CrossRefPubMed
2.
Marusic S, Vlahovic-Palcevski V, Ljubanovic D. Leukocytoclastic vasculitis associated with insulin aspart in a patient with type 2 diabetes. Int J Clin Pharmacol Ther. 2009;47(10):603–605.CrossRefPubMed
3.
Rachid B, Rabelo-Santos M, Mansour E, de Lima Zollner R, Velloso LA. Type III hypersensitivity to insulin leading to leukocytoclastic vasculitis. Diabetes Res Clin Pract. 2010;89(3):e39–40.
4.
Mandrup-Poulsen T, Mølvig J, Pildal J, et al. Leukocytoclastic vasculitis induced by subcutaneous injection of human insulin in a patient with type I diabetes and essential thrombocytemia. Diabetes Care. 2002;25(1):242–243.
5.
Silva ME, Mendes MJ, Ursich MJ, et al. Human insulin allergy-immediate and late type III reactions in a long-standing IDDM patient. Diabetes Res Clin Pract. 1997;36(2):67–70.
6.
Paley R, Tunbridge R. Dermal reactions to insulin therapy. Diabetes. 1952;1(1):22–27.
7.
Arkins JA, Engbring NH, Lennon EJ. The incidence of skin reactivity to insulin in diabetic patients. J Allergy. 1962;33:69–72.
8.
Radermecker RP, Scheen AJ. Allergy reactions to insulin: effects of continuous subcutaneous insulin infusion and insulin analogues. Diabetes Metab Res Rev. 2007;23(5):348–355.
9.
Ghazavi MK, Johnston GA. Insulin allergy. Clin Dermatol. 2011;29(3):300–305.
10.
Mattson JR, Patterson R, Roberts M. Insulin therapy in patients with systemic insulin allergy. Arch Intern Med. 1975;135(6):818–821.
11.
deShazo RD, Boehm TM, Kumar D, et al. Dermal hypersensitivity reactions to insulin: correlations of three patterns to their histopathology. J Allergy Clin Immunol. 1982;69(2):229–237.
12.
Pratt EJ, Miles P, Kerr D. Localized insulin allergy treated with continuous subcutaneous insulin. Diabet Med. 2001;18(6):515–516.
13.
Moyes V, Driver R, Croom A, Mirakian R, Chowdhury TA. Insulin allergy in a patient with type 2 diabetes successfully treated with subcutaneous insulin infusion. Diabet Med. 2006;23(2):204–206.
14.
Grant W, deShazo RD, Frentz J. Use of low-dose continuous corticosteroid infusion to facilitate insulin pump use in local insulin hypersensitivity. Diabetes Care. 1986;9(3):318–319.
15.
Schernthaner G. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care. 1993;16(Suppl 3):155–165.
16.
Léonet J, Malaise J, Goffin E, et al. Solitary pancreas transplantation for life-threatening allergy to human insulin. Transpl Int. 2006;19(6):474–477.
17.
Léonet J, Malaise J, Squifflet JP. Refractory insulin allergy: pancreas transplantation or immunosuppressive therapy alone? Transpl Int. 2010;23(7):e39–40.
18.
Logtenberg SJ, Kleefstra N, Houweling ST, et al. Improved glycemic control with intraperitoneal versus subcutaneous insulin in type 1 diabetes: a randomized controlled trial. Diabetes Care. 2009;32(8):1372–1377.
19.
Cahn A, Miccoli R, Dardano A, Del Prato S. New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes Endocrinol. 2015;3(8):638–652.CrossRefPubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »